Clinical Trials Browser

Phase 1/2 × INDUSTRY × Vaccines, DNA × Clear all

NCT06631092 2026-02-20

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

Phase 1/2 Recruiting

Triple Negative Breast Neoplasms

NCT02529930 2022-07-13

An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)

Phase 1/2 Completed

High Grade Cervical Intraepithelial Neoplasia